What We're Reading: Page 70
Industry reads hand-picked by our editors
Nov 14, 2023
-
Health Affairs
What’s The Worst That Could Happen? A Toothless FDA
-
Fierce Biotech
Hepatitis B drug developers chart slow progress, just like in hep C
-
Regulatory Focus
FDA announces OPQ reorganization to alleviate ‘long-standing pain points’
-
The Transmitter
Making cancer nervous
Nov 13, 2023
Nov 10, 2023
-
Investor’s Business Daily
Amylyx Stock Crashes As Patients Drop Off ALS Drug, Relyvrio
-
Axios
“I’ve never seen anything like this”: High demand fuels drug shortages
-
MIT Technology Review
How open-source drug discovery could help us in the next pandemic
Nov 09, 2023
Nov 08, 2023
-
The Washington Post
Bertagnolli confirmed as new head of National Institutes of Health
-
Bloomberg
Elon Musk’s Neuralink Brain Implant Startup Is Ready to Start Surgery
-
The Wall Street Journal
Same Drug, Two Prices: Why The Higher Price Prevails
Nov 07, 2023
Nov 06, 2023
-
C&EN
Is this a golden age of small-molecule drug discovery?
-
Financial Times
Novo Nordisk warns EU that new rules will push it to expand faster in US
-
FirstWord Pharma
US watchdog calls for more transparency in fair access to drugs
-
PharmaVoice
The thorniest questions facing pharma, according to a leading bioethicist
Previous
